About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Endometrial cancer drug receives breakthrough therapy designation in China 

Mage Biologics created to develop oral antibody therapy for ulcerative colitis

Seven pharma companies form alliance to prepare for future pandemics 

Biomica announces interim positive results from irritable bowel syndrome program

Sosei Heptares hails ‘transformational’ acquisition

Novel bacterial communication system could help take on antimicrobial resistance

ADVERTISEMENT

Moleculin issues acute myeloid leukemia drug data

Korro Bio and Frequency Therapeutics to merge

Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma

FDA approves Beyfortus ahead of 2023-24 RSV season

Hope for Alzheimer’s patients after Lilly drug results

Westlake launches $450M fund for LA biotechs

ADVERTISEMENT